Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 8/20 | 0.85 |
| ▸ | LMNA | P02545 | 2/20 | 0.85 |
| ▸ | PGR | P06401 | 4/20 | 0.80 |
| ▸ | NR3C1 | P04150 | 8/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.72 |
| ▸ | AR | P10275 | 2/20 | 0.72 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.72 |
| ▸ | TNF | P01375 | 1/20 | 0.72 |
| ▸ | IL6 | P05231 | 1/20 | 0.72 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.72 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.72 |
| ▸ | GLUL | P15104 | 1/20 | 0.72 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.72 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.72 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Prednisolone Hemisuccinate SCHEMBL25138782 | 1.00 | HIF1A (0.85) | HIF1ALMNAPGRNR3C1SMN1; SMN2 | |
| Prednisolone Hemisuccinate SCHEMBL945987 | 1.00 | HIF1A (0.85) | HIF1ALMNAPGRNR3C1SMN1; SMN2 | |
| Prednisolone Hemisuccinate SCHEMBL13026153 | 1.00 | HIF1A (0.85) | HIF1ALMNAPGRNR3C1SMN1; SMN2 | |
| Prednisolone Hemisuccinate SCHEMBL12540510 | 1.00 | HIF1A (0.85) | HIF1ALMNAPGRNR3C1SMN1; SMN2 | |
| Prednisolone Hemisuccinate SCHEMBL16009511 | 1.00 | HIF1A (0.85) | HIF1ALMNAPGRNR3C1SMN1; SMN2 | |
| Prednisolone Hemisuccinate SCHEMBL3360749 | 0.99 | HIF1A (0.84) | HIF1ALMNAPGRNR3C1SMN1; SMN2 | |
| Prednisolone Hemisuccinate SCHEMBL27639542 | 0.99 | HIF1A (0.84) | HIF1ALMNAPGRNR3C1SMN1; SMN2 | |
| Prednisolone Hemisuccinate SCHEMBL7155955 | 0.99 | HIF1A (0.84) | HIF1ALMNAPGRNR3C1SMN1; SMN2 | |
| SCHEMBL16009510 | 0.97 | HIF1A (0.91) | HIF1ALMNAPGRNR3C1SMN1; SMN2 | |
| SCHEMBL16170220 | 0.93 | HIF1A (0.85) | HIF1ALMNAPGRNR3C1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 764 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024186108-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATION COMPRISING GLUCOCORTICOID COMPOUND | 주식회사 에스씨엘테라퓨틱스 | 2024-09-12 | — | — | WO | claimed |
| US-20230108050-A1 | CXCL8 (INTERLEUKIN-8) ACTIVITY INHIBITOR AND CORTICOSTEROID COMBINATION AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | DOMPE' FARMACEUTICI SPA (IT) | 2023-04-06 | — | — | US | claimed |
| EP-4106738-A1 | CXCL8 (INTERLEUKIN-8) ACTIVITY INHIBITOR AND CORTICOSTEROID COMBINATION AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Dompe' Farmaceutici SpA (IT) | 2022-12-28 | — | — | EP | claimed |
| CN-113164043-A | Compositions and methods for glaucoma | 奥夫博医疗创新有限公司 | 2021-07-23 | — | — | CN | claimed |
| EP-3709912-A1 | DRUG DELIVERY SYSTEMS AND METHODS | Alcyone Lifesciences, Inc. (US) | 2020-09-23 | — | — | EP | claimed |
| US-20190201416-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF LUNG CANCER COMPRISING GLUCOCORTICOID-BASED COMPOUND | AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2019-07-04 | — | — | US | claimed |
| EP-1744683-B1 | APPARATUS AND METHOD FOR TRANSDERMAL DELIVERY OF PARATHYROID HORMONE AGENTS | ALZA CORP (US) | 2016-03-16 | — | — | EP | claimed |
| US-20150093434-A1 | LIPOSOMAL COMPOSITIONS OF GLUCOCORTICOID AND GLUCOCORTICOID DERIVATIVES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERSUSALEM (IL) | 2015-04-02 | — | — | US | claimed |
| US-8932627-B2 | Liposomal compositions of glucocorticoid and glucocorticoid derivatives | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2015-01-13 | — | — | US | claimed |
| CN-101043875-B | Liposomal compositions of glucocorticoid and glucocorticoid derivatives | YISSUM RES DEV CO | 2014-05-07 | — | — | CN | claimed |
| WO-2006027787-A1 | LIPOSOMAL COMPOSITIONS OF GLUCOCORTICOID AND GLUCOCORTICOID DERIVATIVES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2006-03-16 | — | — | WO | claimed |
| WO-2006027786-A2 | USE OF LIPOSOMAL GLUCOCORTICOIDS FOR TREATING INFLAMMATORY STATES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2006-03-16 | — | — | WO | claimed |
| US-20050245497-A1 | Treatment of ophthalmic conditions | EYE CO PTY LTD (AU) | 2005-11-03 | — | — | US | claimed |
| WO-2005099715-A2 | TREATMENT OF OPHTHALMIC CONDITIONS WITH MINERALCORTICOIDS | RETMED PTY LTD. (AU) | 2005-10-27 | — | — | WO | claimed |
| US-20030236298-A1 | 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders | ATHEROGENICS PHARMACEUTICALS, INC. | 2003-12-25 | — | — | US | claimed |
| US-6608101-B1 | Inflammatory disorders; 3-(2,4-dimethoxy-5-(thien-2-yl)phenyl)-1-(4-carboxymethoxy-3,5 -dimethoxyphenyl)-2-propen-1-one; | ATHEROGENICS, INC. | 2003-08-19 | — | — | US | claimed |
| EP-1330448-A2 | 1,3-BIS-(SUBSTITUTED-PHENYL)-2-PROPEN-1-ONES AND THEIR USE TO TREAT VCAM-1 MEDIATED DISORDERS | Atherogenics, Inc. (US) | 2003-07-30 | — | — | EP | claimed |
| WO-2001098291-A2 | 1,3-BIS-(SUBSTITUTED-PHENYL)-2-PROPEN-1-ONES AND THEIR USE TO TREAT VCAM-1 MEDIATED DISORDERS | ATHEROGENICS, INC. (US) | 2001-12-27 | — | — | WO | claimed |
| WO-1997015298-A1 | COMBINATION OF LTD, RECEPTOR ANTAGONISTS WITH GLUCOCORTICOSTEROIDS | BAYER AKTIENGESELLSCHAFT (DE) | 1997-05-01 | — | — | WO | claimed |
| US-4478818-A | Ocular preparation housing steroid in two different therapeutic forms | ALZA CORPORATION (US) | 1984-10-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230108050-A1 | CXCL8 (INTERLEUKIN-8) ACTIVITY INHIBITOR AND CORTICOSTEROID COMBINATION AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | CXCL8, CCR8, MMP8 | HIF1A 2536/4885LMNA 4459/4885PGR 2508/4885 |
| US-20050245497-A1 | Treatment of ophthalmic conditions | MC2R, NR3C2, PTGIR | HIF1A 1002/4885LMNA 3426/4885PGR 529/4885 |
| US-20030236298-A1 | 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders | VCAM1, ICAM1, ITGB1 | HIF1A 415/4885LMNA 2238/4885PGR 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.